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Abstract
The cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncogenic factor that stabilises the c-Myc protein. CIP2A is
overexpressed in several tumours, and expression levels are an independent marker for long-term outcome. To determine
whether CIP2A expression is elevated in colon cancer and whether it might serve as a prognostic marker for survival, we
analysed CIP2A mRNA expression by real-time PCR in 104 colon cancer samples. CIP2A mRNA was overexpressed in colon
cancer samples and CIP2A expression levels correlated significantly with tumour stage. We found that CIP2A serves as an
independent prognostic marker for disease-free and overall survival. Further, we investigated CIP2A-dependent effects on
levels of c-Myc, Akt and on cell proliferation in three colon cancer cell lines by silencing CIP2A using small interfering (si) and
short hairpin (sh) RNAs. Depletion of CIP2A substantially inhibited growth of colon cell lines and reduced c-Myc levels
without affecting expression or function of the upstream regulatory kinase, Akt. Expression of CIP2A was found to be
dependent on MAPK activity, linking elevated c-Myc expression to deregulated signal transduction in colon cancer.
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Introduction
Colorectal cancer (CRC) is the most common gastrointestinal
malignancy. There are approximately 664,000 new cases each
year worldwide. Half of these patients will die from this carcinoma
[1]. Currently, standard treatment is primary surgery and,
depending on the tumour stage, additional chemotherapy [2].
Due to the high recurrence rate, new potential targets and
prognostic markers are needed to identify patients that are likely to
benefit from additional therapy.
In 2007, Junttila and Westermarck identified the cancerous
inhibitor of protein phosphatase 2A (CIP2A) as a human
oncoprotein. CIP2A is overexpressed in head and neck squamous
cell carcinomas and in colon carcinomas [3]. CIP2A inhibits the
protein phosphatase 2A (PP2A). PP2A in turn has a critical role in
turnover of the c-Myc oncoprotein, since PP2A dephosphorylates
c-Myc at serine-62 (S62). Dephosphorylation at S62 is required for
ubiquitination of c-Myc by the ubiquitin ligase Fbw7 and
therefore, initiates degradation of c-Myc [4]. Overexpression of
CIP2A inhibits PP2A activity and thereby stabilizes c-Myc.
Consequently, this induces immortalisation and malignant trans-
formation of human cells [3]. c-Myc itself remains the most
important oncogenic driver in colorectal cancer [5].
Recent studies have shown that CIP2A is overexpressed in
several human malignancies. CIP2A expression levels correlate
with overall survival (OS) and disease free survival (DFS) in gastric
carcinomas, in serous ovarian cancer, in renal cell carcinoma and
in breast cancer [6;7;8;9]. In chronic myeloid leukemia (CML),
CIP2A expression at the time point of diagnosis is a prognostic
marker for the development of a blast crisis later on [10].
Furthermore, some oncogenic factors, including helicobacter pylori
and papilloma virus 16 E7, upregulate expression of CIP2A and
this may be critical for their oncogenic activity [11;12].
Recently, two groups reported conflicting results regarding the
prognostic impact of CIP2A in colorectal cancer [13,14]. Bo¨ckel-
man et al. studied 752 patients, but could not determine any
prognostic significance; in contrast Teng et al. studied 167 patients
and identified CIP2A expression as a prognostic factor for colon
carcinoma.
The aim of the present study was to address the relevance of
CIP2A expression in colon cancer. First, we analysed expression of
CIP2A in a cohort of 104 colon cancer patients with documented
follow-up and confirmed its overexpression. Secondly, we inves-
tigated the association between CIP2A mRNA expression and
clinical-pathological variables; lastly, we aimed to determine the
molecular pathways that regulate CIP2A expression and, are
regulated by CIP2A. Our data support the notion that deregulated
expression of CIP2A is a critical oncogenic event in colon
carcinoma.
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Patients and Methods
Patient Samples
One hundred and four patients with colorectal cancer were
included in the study. All patients underwent surgery at the
University Hospital of Wuerzburg, Germany, between 2003 and
2012. None of the patients had received chemotherapy or
radiotherapy before surgery. Treatments after surgery were
performed according to guidelines for treating colorectal cancer.
The diagnosis was confirmed by histopathological examination of
the specimens. After surgery, tumour specimens were collected
and stored in liquid nitrogen. Clinical data of all the patients were
collected from hospital records and subsequent records were
collected via the Comprehensive Cancer Centre Mainfranken.
Ethics Statement
Ethical approval for this research was obtained from the
Human Research Ethics Committee of the University of
Wuerzburg. All patients that provided tumor tissue and normal
colon tissue samples for this research signed a consent form prior
to surgical removal of the intestinal cancer.
Cell Lines and Cell Culture
Caco2, HCT116, and SW620 cells were purchased from
American Type Culture Collection. All cells were cultured in
DMEM supplemented with 10% fetal calf serum und 1%
penicillin/streptomycin.
Real-time Quantitative Reverse Transcription-PCR
Analysis
Gene expression of CIP2A was analysed using real-time PCR.
Total cellular RNA was extracted from tumour samples and cell
lines with RNeasy Minikit (Qiagen; Hilden, Germany) according
to the manufacturer’s instructions. Primer sets (Qiagen) that
targeted CIP2A RNA were designed by Biomers (Ulm, Germany).
Matched human colon cDNA (Pharmingen; Heidelberg, Ger-
many) served as a positive control, standardized to baseline. The
housekeeping genes, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and beta-2 microglobulin (b2MG) were used as internal
standards for relative quantification and cDNA quality control. All
PCR reactions were carried out with a DNA Engine Opticon 2
System (MJ Research, Biozym; Oldendorf, Germany). Relative
quantification, based on the fold difference, was calculated with
the threshold cycle (Ct) method, expressed as 22DDCt (Primer
sequence in Table S1).
Immunoblot Analysis
Cultured cells were rinsed three times with ice-cold PBS,
harvested, and lysed directly in RIPA sample buffer for
Immunoblot analysis. Cell debris was removed by centrifugation
at 12,000 g for 10 min at 4uC, and the supernatant was used as
total protein lysate. For each sample, 10 mg of total protein lysate
was subjected to 10% sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-Page), followed by Immunoblot analysis.
Immunoblots were probed with antibodies against CIP2A (A301-
Figure 1. CIP2A mRNA expression is significantly correlated with advanced tumour stage. The panels show box and whisker plots
documenting relative CIP2A mRNA levels in tumors stratified according to UICC stage (A) (UICC I vs. II p,.0001; II vs. III p = .0046; III vs. IV p = .0002),
according to lymph node metastasis (B; N- vs. N+ p,.0001), according to distant metastasis (C; M0 vs. M1 p,.0001), and according to histological
grading (D: G2 vs. G3 p= .0084).
doi:10.1371/journal.pone.0075292.g001
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454A; Bethyl Laboratories), c-Myc C33 (C33, #42; Santa Cruz),
beta-actin (AC-15/A5441; Sigma), vinculin (V9131; Sigma), AKT,
pAKT473 (cs-9271), gsk3 (cs-9315), pGSK Serine-9 (cs-9336), s6
(cs-2212), ps6 (cs-2215); pmTOR (cs-2917), and mTOR (cs-2972).
All antibodies were from Cell Signalling and were used according
to the manufacturer’s instructions. The blots were visualised with
secondary antibodies (GE Healthcare) against mouse (NA9310) or
rabbit (NA9340) primary antibodies.
Table 1. Univariate 1, 3, 5-year overall survival of CRC patients.
1-Year (n=74) 3-Year (n =58) 5-Year (n =55)
Parameters Total
overall
survival p-value Total
overall
survival p-value Total
overall
survival p-value
T stage T1,2 9 100% ,0.0001 5 80.0% 0.0014 4 75.0% 0.0004
T3,4 64 75% 53 59.6% 50 52.0%
N Stage N0 32 93.8% ,0.0001 23 82.6% ,0.0003 22 77.3% ,0.0004
N1,2 41 65.9% 34 47.1% 32 37.5%
M stage M0 50 100% ,0.0001 36 94.4% ,0.0001 33 84.9% ,0.0001
M1 23 30.4% 21 4.8% 21 4.8%
UICC stage I-II 29 100% ,0.0001 20 95.0% ,0.0001 19 89.5% ,0.0001
III-IV 44 63.6% 37 43.2% 35 34.3%
Histological grade G2 56 83.9% ,0.04 42 66.7% ,0.05 40 60.0% 0.0506
G3 17 58.8% 15 46.7% 14 35.7%
CIP2A expression , median 32 100% ,0.0001 22 95.5% ,0.0001 20 95.0% ,0.0001
. median 41 61.0% 34 41.2% 34 29.4%
doi:10.1371/journal.pone.0075292.t001
Figure 2. Patients with CIP2A high mRNA expression have an overall lower survival rate than patients with CIP2A low mRNA
expression. The graphs show Kaplan–Meier curves of OS according to CIP2A mRNA expression. (red: CIP2A mRNA expression below median fold
expression value of 10,5 above normal tissue), green: CIP2A mRNA expression above median fold expression value of 10,5 above normal tissue) (A &
B) All patients with respect to CIP2A mRNA expression normalized to housekeeping gene (n = 75) (A: b2MG; B: GAPDH) (C) Patients in Stage UICC II
with respect to CIP2A mRNA expression normalized to housekeeping gene GAPDH (n= 29) (D) Patients in Stage UICC III with respect to CIP2A mRNA
expression normalized to housekeeping gene GAPDH (n= 21).
doi:10.1371/journal.pone.0075292.g002
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Immunohistochemistry
The CIP2A antibody was the same as for Immunoblot analysis,
isotype control antibody was purchased from eBioscience (San
Diego, USA). The secondary antibody was a Cy3-conjugated
AffiniPure anti-rabbit IgG at a 1:200 dilution. CIP2A staining was
performed on cryostat sections of snap-frozen colon cancer
specimens expressing different CIP2A mRNA levels with neigh-
bouring normal colon tissue and 10 normal colon specimens.
Cryostat sections (5 mm) were incubated with the primary
antibody or control antibody followed by incubation with the
secondary Cy3-conjugated antibody. Slides were counterstained
with DAPI (49,6-Diamidino-2-phenylindoldihydrochlorid) (Sigma-
Aldrich, Steinheim, Germany) and covered with polyvinyl-alcohol
mounting medium (DABCO, Sigma-Aldrich) and analysed using a
Zeiss camera (Oberkochen, Germany).
siRNA Transfection
To silence gene expression, cells were transfected with small
interfering RNAs (siRNAs). On-target plus SMART pool
(Dharmacon) siRNA to target CIP2A (L-014135-01-005) and a
control siRNA (D-001810-10-05) were used. The siRNA pools
(final concentration 100 nM) were transfected into the cells with
the RNAimax kit according to the manufacturer’s protocol. Cells
were harvested 72 h later; expression of proteins was determined
by Immunoblot analysis.
shRNA and Lentivirus
To silence CIP2A mRNA expression with short hairpin RNA
(shRNA) sequences, targeting CIP2A were cloned into a lentivirus
vector (plko1 puro), according to the manufacturer’s protocol. The
vector was transiently transfected into HEK293t cells together
with package plasmids. After 48 and 72 h, supernatants containing
the virus were collected and filtered. Colon cancer cell lines were
infected with the CIP2A lentivirus and 24 h later, infected cells
were selected with puromycin. Experiments were performed with
the selected cells.
Colony Formation Assay
2.56103 cells infected with shRNA CIP2A or Scr. were plated
on six well plates. Colonies were stained with 0.5% crystal violet in
20% ethanol. Photos were taken and relative density determined
with ImageJ.
Statistical Analysis
Univariate analyses to determine association with survival were
evaluated with Kaplan–Meier curves, and comparisons were
performed by Mann-Whitney U test. Multivariate analyses were
performed with a Cox proportional hazards regression model. P-
values ,0.05 were considered statistically significant.
Table 2. Cox regression analysis in predicting the overall
survival of CRC patients.
Risk factors HR 95% CI p-value
UICC stage 2.38 1.38–4.1 ,0.01
Histological grade 1.03 0.49–2.16 n.s.
CIP2A expression (above median vs.
below median)
3.06 1.27–7.37 ,0.05
CIP2A expression (continues factor) 1.02 1.0–1.05 ,0.02
(HR Hazard ratio).
doi:10.1371/journal.pone.0075292.t002
Figure 3. CIP2A protein levels in colon cancer correlate with CIP2A mRNA expression. The panels show representative examples of
immunofluorescence staining, showing CIP2A protein expression in cancer cells of patients with low (A+B) or high CIP2A (C+D) mRNA expression
(A+C x100, B+D x200 magnification).
doi:10.1371/journal.pone.0075292.g003
CIP2A in Colon Cancer
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Figure 4. Depletion of CIP2A downregulates c-Myc protein expression in colon cancer cells. (A) Immunoblot analysis of CIP2A and c-Myc
protein expression in Caco2, HCT116 and SW620 cells transfected with siRNA targeting CIP2A or control siRNA. Cells were harvested 72 h after
transfection (n = 3 for each cell line). (B) Real-time PCR analysis of CIP2A and c-Myc mRNA expression in HCT116 cells transfected with siRNA targeting
CIP2A or control siRNA (n = 3). (C) Depletion of CIP2A does not change activation status of AKT or its downstream targets. The panels show
immunoblots of the indicated proteins and phosphorylated proteins (p) in Caco2, HCT116 and SW620 cells transfected with siRNA targeting CIP2A or
control siRNA as before (n = 3 for each cell line).
doi:10.1371/journal.pone.0075292.g004
CIP2A in Colon Cancer
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Results
Expression of CIP2A and Clinicopathological Variables of
Colon Cancer Patients
Expression of CIP2A mRNA was initially assessed using
expression data sets derived from a published microarray analysis,
which was originally performed to identify prognostic markers for
colorectal carcinomas according to the lymph node metastasis
status [15]. Complete data sets (DFS, Tumor stages), comparing
CIP2A mRNA expression in carcinoma to that in matched
adjacent tissues, were available for 226 carcinomas. CIP2A
expression was tested using two independent probes present on
this array. We found no correlation between CIP2A expression and
age at diagnosis, or gender in this data set, but CIP2A mRNA was
expressed at higher levels in colorectal cancer tissues than in the
matched adjacent tissues in both probe sets (data not shown).
Intriguingly, high CIP2A mRNA expression correlates significantly
with reduced disease-free survival (DFS) (Fig. S1A, B). In separate
analyses of patients in Union for International Cancer Control
(UICC) stage I (tumour infiltration to muscularis propria), II
Figure 5. CIP2A is required for growth of HCT116 cells. (A) Immunoblot analysis of CIP2A and c-Myc protein expression in HCT116 cells
infected lentiviral with shRNA targeting CIP2A or a ctr. shRNA. Numbers below lines indicate the c-myc protein expression relative to c-myc levels in
control cells (n = 2). (B) Colony formation of HCT116 cells after 7 days. (Top), density of colonies stained with crystal violet; (bottom), representative of
the indicated cultures (n = 3).
doi:10.1371/journal.pone.0075292.g005
Figure 6. CIP2A expression is regulated by MAPK signalling. Caco2, HCT116 and SW620 cells were treated with DMSO or the MEK inhibitor
UO126 for 24 h (n = 3 for each cell line). (A) Immunoblot analysis of CIP2A and p-ERK protein expression in Caco2, HCT116 and SW620. (B) Real-time
PCR analysis of CIP2A mRNA expression (*,0.05; **,0.005).
doi:10.1371/journal.pone.0075292.g006
CIP2A in Colon Cancer
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(tumour infiltration beyond muscularis propria) or III (lymph node
metastasis), only patients in stage UICC III showed a significant
correlation between CIP2A expression and DFS. In comparison,
patients in stage UICC I and II showed only a slight correlation
between low CIP2A expression and prolonged survival that did not
reach statistical significance. This may be due to the small number
of samples and fewer relapse events in comparison to patients in
stage UICC III (Fig. S2A–C). As DFS could not be reached in
stage UICC IV (distant metastases), it was not possible to analyse
the correlation of CIP2A expression to the survival of patients in
stage UICC IV with this data set.
We further analysed CIP2A mRNA levels in an independent set
of 104 colorectal cancer tissue samples using an RT-QPCR
approach. The expression of CIP2A mRNA was determined
relative to two housekeeping genes, beta-2 microglobulin (b2MG)
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The
expression levels were compared to the median CIP2A mRNA
expression in normal mucosal tissue. CIP2A expression relative to
b2MG or relative to GAPDH showed a high correlation (R2= 0.86)
(Fig. S3). Consistent with previous findings on CIP2A expression
in cancer, we found CIP2A mRNA expression in 93 of 104 (89.4%)
cancer samples to be at least four times higher than in normal
colon mucosal tissues. Furthermore, CIP2A expression level was
significantly correlated to the UICC stage, lymph node metastasis,
distant metastasis, and histological tumour grading (Fig. 1). We
found no association between CIP2A expression and patient age,
gender or cancer location (right vs. left colon) (Table S2).
CIP2A mRNA Expression and Postoperative Survival of
Colon Cancer Patients
Overall survival (OS) was used for survival analysis. Overall
survival was defined as the time interval between surgery and
tumour-associated death. Univariate 1-, 3-, and 5-year OS
analyses revealed that patients with an advanced primary tumour
stage, lymph node metastasis, distant metastasis, advanced UICC-
stage, and high histological grades had worst outcomes (Table 1).
For further analysis, patients were divided into two groups, with
CIP2A expression above (high) or below (low) median value.
Patients with high CIP2A mRNA expression had significantly
lower OS than those with low CIP2A mRNA expression (Fig. 2A,
B). Comparing patients in UICC stages I-IV separately with high
and low CIP2A mRNA expression, only in the UICC III stage,
patients with high CIP2A levels had a reduced OS (Fig. 2C, D). In
addition, a multivariate analysis indicated that an advanced
UICC-stage and high CIP2A expression (CIP2A above median and
CIP2A expression used as a continuous marker) were independent
prognostic factors for poor outcome in patients with colon cancer
(Table 2).
To test whether CIP2A mRNA expression is correlated with
CIP2A protein expression in CRC, ten normal mucosa tissue
sections, four CRC tissue samples expressing low CIP2A mRNA
levels and five tissue samples expressing high CIP2A mRNA levels
were stained for CIP2A protein expression. In normal mucosa
tissue sections, no or only a very weak staining for CIP2A could be
detected (data not shown). Cancers expressing low levels of CIP2A
mRNA showed a weak staining for CIP2A protein, whereas
cancers expressing high CIP2A mRNA levels showed a strong
staining for CIP2A protein. This results show that CIP2A protein
and mRNA levels correlate closely in vivo. (Fig. 3).
Effects of CIP2A Depletion on Cell Growth and Myc
Expression in CRC
We further wanted to clarify the influence of CIP2A on its target
proteins in CRC cell lines. Protein expression of CIP2A was
remarkably reduced in three colon cell lines (Caco2, HCT116 and
SW620) after treatment with specific siRNA against CIP2A.
Furthermore, CIP2A knockdown led to substantial reductions in c-
Myc levels in all three cell lines (Fig. 4A; n= 3 for each cell-line).
This was due to posttranscriptional regulation of c-Myc protein
levels, since we detected no change in MYC mRNA expression
(Fig. 4B; n= 3). Previous studies indicated that CIP2A knockdown
led to a reduced activity of Akt, shown by reduced phosphory-
lation at serine 473 (pAkt473), and thereby, inhibited the PI3K/
mTor pathway. However, we did not detect any significant
changes in phosphorylated Akt after CIP2A knockdown in Caco2,
HCT116 or SW620 cells. Furthermore, phosphorylation of the
downstream Akt targets, including pmTor, pS6, and pGsk3, was
not significantly altered after knockdown of CIP2A (Fig. 4C; n = 3
for each cell line). Overall, this shows that c-Myc protein is under
the control of CIP2A in CRC, whereas the PI3K/mTor appears
to be independent of CIP2A.
Because siRNAs are typically lost over time, and to exclude off-
target effects, we tested two different shRNAs targeting CIP2A to
evaluate the growth inhibiting effect of CIP2A knockdown.
HCT116 cells were infected lentiviral with vectors carrying
shRNAs against CIP2A. Immunoblot analyses showed substantial
knockdown of CIP2A protein with corresponding reduction in c-
Myc protein levels (Fig. 5A; n= 2). Accordingly, cell proliferation
was markedly altered in cells infected with shRNA against CIP2A
(Fig. 5B; n= 2).
CIP2A Expression is Downstream of MEK Kinase in CRC
To identify potential upstream regulators of CIP2A expression,
we treated Caco2, HCT116 and SW620 cells with UO126, a well-
characterised Mek1/2 inhibitor [16]. Treatment with UO126 for
24 h led to a significant reduction in CIP2A mRNA and CIP2A
protein expression compared to DMSO treated cells (Fig. 6A, B;
n = 3 for each cell line). This effect was more pronounced in cells
that harboured a MAPK pathway mutation, such as SW620
(KRAS) and HCT116 (KRAS), than in Caco2 cells that are wild type
for KRAS.
Discussion
Recently ‘‘The Cancer Genome Atlas Network’’ demonstrated
that deregulated c-Myc expression is a hallmark of virtually all
CRCs, independent of the set of specific mutations that are present
in each tumour [5]. For example, mutations in the tumour
suppressor APC and the oncogene KRAS lead to an upregulation of
MYC mRNA [5]. On posttranscriptional level, the loss of miR34
family by hypermethylation, which occurs in over 90% of all
CRC, stabilizes MYC mRNA [17,18]. Furthermore, a mouse
model of colon cancer driven by loss of APC shows that colon
tumour formation depends on continuous c-Myc expression [19].
So far, little is known about the posttranslational regulation of c-
Myc levels in CRC. In the present study, we demonstrated that
CIP2A expression is elevated in colon carcinoma samples,
compared to its expression in normal, large intestine tissue, and
that CIP2A expression is negatively correlated to both OS and
clinical pathological parameters. Since there are no validated cut-
off points for CIP2A expression levels to clarify high vs. low
expression groups, we used the median mRNA expression level as
the cut-off point. Despite a relatively low number of patients in our
study, and therefore a relatively low number of cancer-related
CIP2A in Colon Cancer
PLOS ONE | www.plosone.org 7 October 2013 | Volume 8 | Issue 10 | e75292
deaths in subgroup analyses, we could demonstrate a significant
correlation of CIP2A levels with tumour-associated survival.
Two previous studies analysed expression levels of CIP2A in
CRC and demonstrated enhanced levels in CRC relative to
normal mucosa, consistent with the results reported here [13,14].
Furthermore, a close correlation between CIP2A and Myc levels
has been noted before [3,13] and we show here that elevated levels
of CIP2A are required to maintain Myc expression in CRC cell
lines. Surprisingly, correlation with OS was seen in only one of the
previous studies [14]. While we do not know the precise reason for
the discrepancy, we note that both Teng et al. [14] and our study
assigned a relatively high percentage of patients to the low
expression group (68 and 50% respectively), whereas Bo¨ckelman
et al. [13] defined only 15% of patients as low CIP2A expression
tumours. We suggest that these differences in the stratification of
patients according to CIP2A levels may account for the different
results. The notion that CIP2A is overexpressed in colon cancer,
thereby enhancing Myc protein levels and influencing tumour
related survival, is consistent with previous results in other solid
tumours [6;7;8;9]. A prospective study will be required to evaluate
if CIP2A expression on mRNA or protein level can serve as a
predictive marker for the survival of patients with CRC.
It was shown previously that CIP2A stabilises c-Myc by
inhibiting its PP2A-mediated degradation in tumour cells [3].
Consistent with this model, the present study shows that
downregulation of the c-Myc protein is observed when CIP2A is
silenced with siRNAs or shRNAs in colorectal carcinoma cells.
Due to the fact that we used cell lines harbouring different
mutations for oncogenic pathway commonly mutated in CRC
(Caco2: APCmut, KRASwt, Pi3Kwt; HCT116: APCwt, ß-catenin-
mut, KRASmut, Pi3Kmut; SW620: APCmut, KRASmut, Pi3Kwt), we
postulate that the dependence of c-Myc protein expression on
CIP2A is independent of the presence of mutations in WNT,
PI3K/mTor or MAPK-pathways, but this will need to be
evaluated further. We also found that shRNA-mediated depletion
of CIP2A in HCT116 colon carcinoma cells markedly reduced
their growth potential. This is consistent with reports that CIP2A
inhibition resulted in growth arrest and diminished clonogenic
potential in several other malignancies [6;7;8].
PP2A dephosphorylates pAkt and CIP2A enhances PI3K/
mTor signalling by inhibiting PP2A mediated dephosphorylation
of pAKT in hepatocellular carcinomas (HCC) [20;21,22]. Our
results show that depletion of CIP2A expression in colorectal
cancer cells does not affect Akt signalling, in contrast to
observations in HCC cells. We also found no or only minor
changes in the pAkt levels or known Akt downstream targets. Most
likely, therefore, PP2A activity towards some of its substrates (Akt)
differs between different tissues.
Little is known about the mechanism underlying the enhanced
expression of CIP2A in malignant cells. In gastric cancer,
helicobacter pylori infections up-regulate CIP2A expression through
a Src/Erk dependent pathway [11]. The human papillomavirus
16E7 oncoprotein upregulates CIP2A in cervical cancer [12]. It is
currently unclear what contributes to CIP2A overexpression in
colon cancer. Two findings support the hypothesis that CIP2A
expression in colon cancer is downstream of the MAPK pathway.
First, previous work showed that CIP2A expression is positively
correlated with EGFR expression [13]. The MAPK pathway is
one of the major targets of EGF signalling. Second, we showed
that CIP2A is downregulated after inhibiting the MAPK pathway
in three colon carcinoma cell lines; downregulation in cell lines
harbouring a KRAS mutation (HCT116, SW620) is more
pronounced than in Caco2 not harbouring a MAPK-pathway
mutation. Induction of CIP2A may, therefore, be a critical
mediator that links deregulated mitogenic signalling to enhanced
c-Myc expression in CRC.
In conclusion, the results of this study show that CIP2A is
associated with colorectal cancer related survival. High expression
of CIP2A mRNA is correlated with reduced DFS and OS.
Therefore, CIP2A represents a new prognostic factor in the
diagnosis of colorectal cancer. In addition, CIP2A may be a
promising therapeutic target in the development of therapies for
colorectal cancer.
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